INTRODUCTION
Investors in Pharma Services M&A faced formidable challenges in 2023, marked by high interest rates, dwindling deal volumes and pricing disparities between buyers and sellers.
However, optimism is increasing in 2024 as updated valuation models gradually bridge pricing gaps amid a more stable interest rate trajectory. The upcoming UK general election this year may spur further deal activity in H1, as the sector aims to preempt any potential tax alterations.
Simultaneously, as the pharma industry grapples with rising complexities in drug development, there is an imperative to acquire specialized expertise and quicker time-to-market solutions . Certain players, particularly those within the Outsourced Pharma Services space, stand to benefit from these dynamics.
To learn more about the key M&A trends taking shape this year in the Pharma Services space, read our latest paper.
DOWNLOAD THE FULL PAPER
Medical Consumables M&A Market
June 5, 2025
The medical consumables sector is a vital component of healthcare, underpinning diagnostics, treatment, and infection prevention. With a global market projected to grow from $422 billion in 2025 to $571 billion by 2035, at a CAGR of 3.2%, the sector is poised for steady expansion.
Social Care M&A Market
April 25, 2025
The social care sector is a cornerstone of society, contributing £50 billion annually to the UK economy. It plays a vital role in supporting the well-being and diverse needs of our population. However, it now stands at a critical juncture.
GLOBAL CONSUMER HEALTH M&A MARKET
February 27, 2025
The Consumer Health market, currently valued at over $357 billion globally, is projected to almost double by 2034. Through 2025 and onwards, the Consumer Health market is poised for steady growth. The currently fragmented sector offers potential for roll-up opportunities, driven by widespread demand for an integrated offering.
CONTRACT DEVELOPMENT AND MANUFACTURING ORGANISATIONS M&A MARKET
December 2, 2024
The global Contract Development and Manufacturing Organisations (CDMOs) market, which helps Pharmaceutical and MedTech companies in efficiently developing, manufacturing, and bringing products to market, is valued at $230 billion in 2024, and is anticipated to grow at a CAGR of 8.5% to reach $358 billion by 2029.
